Date: 2018-05-03
Type of information: Nomination
Compound: chief technology officer
Company: Sangamo Therapeutics (USA - CA)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On May 3, 2018, Sangamo Therapeutics announced the promotion of Michael Holmes, Ph.D. to Senior Vice President and Chief Technology Officer. Holmes joined Sangamo in 2001 and has served as Vice President of Research since 2015. During his tenure at Sangamo, he has pioneered the use of zinc finger nucleases (ZFNs) for genome editing in transformed and primary human cells, including hematopoietic stem cells and T cells. Holmes is a member of Sangamo's Executive Leadership Team.
Financial terms:
Latest news:
Is general: Yes
